{"id":242725,"date":"2025-06-20T04:47:48","date_gmt":"2025-06-20T04:47:48","guid":{"rendered":"https:\/\/pharmeasy.in\/blog\/?p=242725"},"modified":"2026-03-25T11:34:21","modified_gmt":"2026-03-25T11:34:21","slug":"mounjaro-vs-zepbound-differences-uses-side-effects-more","status":"publish","type":"post","link":"https:\/\/pharmeasy.in\/blog\/mounjaro-vs-zepbound-differences-uses-side-effects-more\/","title":{"rendered":"Mounjaro vs Zepbound: Differences, Uses, Side Effects & More"},"content":{"rendered":"\n\n<\/head>

\n

Table of Contents<\/p>\nToggle<\/span>

Introduction<\/a><\/li>
Zepbound vs Mounjaro<\/a><\/li>
How Do Zepbound and Mounjaro Work?<\/a><\/li>
FDA-Approved Uses and Dosing<\/a><\/li>
Which Conditions Do They Help Manage?<\/a><\/li>
Side Effects: Zepbound vs Mounjaro Safety Comparison<\/a><\/li>
Cost and Availability: India and Global<\/a><\/li>
Are Zepbound and Mounjaro Interchangeable?<\/a><\/li>
Conclusion<\/a><\/li>
Frequently Asked Questions (FAQs)<\/a><\/li>
References<\/a><\/li><\/ul><\/nav><\/div>\n
<\/span>Introduction<\/strong><\/span><\/h2>\n\n\n\nMounjaro and Zepbound are two injectable medications that have gained attention for their roles in managing chronic health conditions. While both contain the same active ingredient, tirzepatide<\/a><\/strong>, they are FDA-approved for different uses: Mounjaro is approved for the treatment of type 2 diabetes (T2DM), whereas Zepbound is approved for chronic weight management in adults with obesity or overweight (with at least one weight-related condition)^{1<\/sup><\/a>^,<\/sup>}^{2<\/sup><\/a>.\u00a0<\/p>\n\n\n\n}
People often compare Mounjaro and Zepbound because they share the same mechanism of action but are marketed for different health conditions. Through this article, we aim to understand the differences between Zepbound vs Mounjaro better, their effectiveness, dosing, side effects, and suitability for different health goals.\u00a0<\/p>\n\n\n\n
<\/span>Zepbound vs Mounjaro<\/strong><\/span><\/h2>\n\n\n\n
$\"zepbound$ <\/figure><\/div>\n\n\n
While Zepbound and Mounjaro share the same active ingredient, their approved uses and practical applications differ. Below is a side-by-side look at how they compare across key metrics ^{3<\/sup><\/a>^,<\/sup>}^{5<\/sup><\/a>:\u00a0<\/p>\n\n\n\n}
Category<\/strong>\u00a0<\/td> Zepbound<\/strong>\u00a0<\/td> Mounjaro<\/strong>\u00a0<\/td><\/tr>
Brand Name\u00a0<\/td> Zepbound\u00a0<\/td> Mounjaro\u00a0<\/td><\/tr>
Generic Name (active ingredient)\u00a0<\/td> Tirzepatide\u00a0<\/td> Tirzepatide\u00a0<\/td><\/tr>
Manufacturer\u00a0<\/td> Eli Lilly and Company\u00a0<\/td> Eli Lilly and Company\u00a0<\/td><\/tr>
CDSCO Approval Year\u00a0<\/td> Not approved yet in India\u00a0<\/td> 2024\u00a0<\/td><\/tr>
FDA Approval Year\u00a0<\/td> 2023\u00a0<\/td> 2022\u00a0<\/td><\/tr>
FDA-Approved Use\u00a0<\/td> Chronic weight management\u00a0<\/td> Type 2 diabetes management\u00a0<\/td><\/tr>
Indications\u00a0<\/td> Obesity (BMI \u226530) or overweight (BMI \u226527) with at least one weight-related condition (e.g., hypertension)\u00a0<\/td> Type 2 diabetes, along with diet and exercise\u00a0<\/td><\/tr>
Mechanism of Action\u00a0<\/td> Dual GIP and GLP-1 receptor agonist\u00a0<\/td> Dual GIP and GLP-1 receptor agonist\u00a0<\/td><\/tr>
Dosing\u00a0<\/td> Once-weekly injection. From 2.5 mg to 15 mg\u00a0<\/td> Once-weekly injection. Doses from 2.5 mg to 15 mg\u00a0<\/td><\/tr>
Starting Dose<\/td> Mounjaro 2.5mg Kwikpen<\/a> (2.5 mg \/ 0.5 ml)<\/td> 2.5mg<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
\n
There is a growing trend to prescribe Mounjaro (off label) in pre-diabetic individuals as can be seen from consumer confessions^{10<\/a><\/sup>.<\/p>\nDr. Nayana Shetty ,MBBS, MD<\/a><\/strong><\/cite><\/blockquote>\n\n\n\n}
<\/span>How Do Zepbound and Mounjaro Work?<\/strong><\/span><\/h2>\n\n\n\nBoth Zepbound and Mounjaro contain tirzepatide, a unique medication that works through dual incretin receptor agonism, targeting both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors ^{6<\/sup><\/a>. This dual action sets tirzepatide apart from older treatment options that target GLP-1 alone.\u00a0<\/p>\n\n\n\n}
GLP-1 Mechanism: <\/strong>GLP-1 is a hormone released in the gut after eating. Tirzepatide enhances GLP-1 activity, which^{6<\/sup><\/a>^,<\/sup>}^{7<\/sup><\/a>:\u00a0<\/p>}
<\/div>